Skip to main content
Top
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study

Authors: G Moyle, C Orkin, M Fisher, J Anderson, J Dhar, MH Wang, J Ewan

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

Dyslipidemia in persons with HIV contributes significantly to cardiovascular (CV) risk. Abacavir (ABC) has been shown to increase lipid levels and some cohort studies have suggested an association between ABC use and myocardial infarction (MI). Comparative data suggested Truvada (TDF/FTC) has a lesser effect on lipid parameters than Kivexa [KVX]. We investigated the change in fasting lipid parameters in hypercholesterolemic subjects switching from KVX + Efavirenz [EFV] to Atripla [ATR]. …
Metadata
Title
Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study
Authors
G Moyle
C Orkin
M Fisher
J Anderson
J Dhar
MH Wang
J Ewan
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P80

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue